Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement
Portfolio Pulse from
Stevanato's Q3 2024 sales exceeded estimates, but adj. EBITDA and EPS fell short due to under-utilization and higher costs in the Engineering division. Despite these challenges, sequential margin improvement is expected, and long-term growth remains strong. The buy rating is maintained.
November 13, 2024 | 6:30 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Stevanato's Q3 2024 sales exceeded expectations, but adj. EBITDA and EPS were below estimates due to under-utilization and higher costs. Despite these issues, the company expects margin improvement and maintains a strong long-term growth outlook.
The sales exceeding estimates is a positive sign, but the shortfall in adj. EBITDA and EPS due to under-utilization and higher costs is a concern. However, the expectation of margin improvement and strong long-term growth outlook balances the short-term negative impact, leading to a neutral short-term price direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100